Skip to main content

Tweets

My take on diet based intervention studies presented at #EULAR2026 It's all in the title: Diet as a DMARD? The Evidence Is Still Hard to Swallow https://t.co/JDVlaOsC6w Head to @RheumNow.com to have a read and for more faculty articles! https://t.co/luV3zZTKOU https://t.co/xHq23oYpjY
Dr. John Cush @RheumNow ( View Tweet )
11 hours 59 minutes ago
An IL-23i through ~5 years: How did clinical manifestations of PsA and radiographic progression change during long-term treatment? 🔥View the latest long-term data from ACR to find out more. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/KfkpMpciEf https://t.co/As0CyHDP8p
Dr. John Cush @RheumNow ( View Tweet )
13 hours 29 minutes ago
Is it all over for avacopan? #Vasculitis https://t.co/1sFUidC6Cw
16 hours 29 minutes ago
RT @jiharheum : ETA+MTX vs triple therapy after MTX failure in #RA: machine learning-emulated RACAT trial (n=3,472 VA pts) confirms ETA+MTX modestly better overall. But smoking matters: benefit disappears in current smokers. Precision medicine from RWD. #EULAR2026 POS0255

Dr. John Cush @RheumNow ( View Tweet )

16 hours 59 minutes ago
RT @drminidey #OP0208 #EULAR2026: phase 3 COURAGE-RA trial showed strong efficacy for selective JAK1 inhibitor zemprocitinib in D2T RA after bDMARD failure. Responses were rapid (from week 2), sustained through week 24 and achieved with a reassuring safety profile.

Dr. John Cush @RheumNow ( View Tweet )

18 hours 59 minutes ago
Which is NOT a key feature of inflammatory back pain: relief with activity; morning stiffness; age under 40 years; unilateral pain? Test your knowledge in this week's RheumIQ quiz at https://t.co/z8mLbcgE5D. https://t.co/tOdPfEBJa4
Dr. John Cush @RheumNow ( View Tweet )
20 hours 29 minutes ago
Obexelimab in IgG4-Related Disease: INDIGO Trial Dr. Henrique Dalmolin reports on abstract OP018 from EULAR 2026. https://t.co/Wid9ZzESae https://t.co/Qo4y8ebkOn
Dr. John Cush @RheumNow ( View Tweet )
21 hours 58 minutes ago
2026 Guidelines for the Treatment of Axial Spondyloarthritis New guidelines offer clinicians and patients clearer directions on diagnostic workup, treatment selection, and long-term disease management, while emphasizing shared decision-making due to ongoing evidence gap. https://t.co/SUFnOMAUw8
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Self-Directed Cognitive Behavioral Therapy for Chronic Pain Is self-directed cognitive behavioral therapy (CBT) when augmented with asynchronous, personalized feedback for chronic pain (CBT-CP) superior to clinician-delivered CBT-CP? https://t.co/P2DDvCiLNL https://t.co/hyAArEG6V1
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
EULAR26: Pitfalls in T2T EULAR recommends T2T strategy in the management of RA and other RMD aiming for clinical remission or low disease activity guided by frequent monitoring and prompt therapy adjustments. But real-world daily implementation in remains poorly investigated. https://t.co/V6mCcdmyJz
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
2-Gene Blood Test for Kawasaki Disease in Febrile Children JAMA Network Open has publshed that a simple 2-gene blood test may aid the earlier diagnosis of Kawasaki disease in children with febrile illnesses. https://t.co/Pwb23fOcO9 https://t.co/P6g23uJzNb
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
True or False: A 5-year retrospective study found that platelet-rich plasma injections significantly outperformed NSAIDs when given to early knee osteoarthritis patients. See if you got it right in this week's RheumIQ quiz at https://t.co/Z8XFynKJ0o. https://t.co/Eu82fctE4B
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
×